Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

Rik Ossenkoppele(Malmö University), Oskar Hansson(Eli Lilly (United States)), Clifford R. Jack(Mayo Clinic), Joseph Therriault(Douglas Mental Health University Institute), Alexa Pichet Binette(Lund University), Divya Bali(Malmö University), James D. Doecke(Royal Brisbane and Women's Hospital), Randall J. Bateman(Washington University in St. Louis), Christopher C. Rowe(The University of Melbourne), Sebastian Palmqvist(Skåne University Hospital), Erik Stomrud(Lund University), Wiesje M. van der Flier(Amsterdam Neuroscience), Erin M. Jonaitis(University of Wisconsin–Madison), Emma M. Coomans(Amsterdam Neuroscience), Elsmarieke van de Giessen(Amsterdam Neuroscience), Azadeh Feizpour(Florey Institute of Neuroscience and Mental Health), Ronald C. Petersen(Mayo Clinic in Arizona), Niklas Mattsson(Malmö University), Nesrine Rahmouni(McGill University), Colin L. Masters(Mental Health Research Institute), Gemma Salvadó(Lund University), Charlotte E. Teunissen(Amsterdam Neuroscience), Suzanne E. Schindler(Washington University in St. Louis), Sylvia Villeneuve(Douglas Mental Health University Institute), Shorena Janelidze(Lund University), Sterling C. Johnson(Wisconsin Society for Cardiovascular and Pulmonary Health & Rehabilitation), Pedro Rosa‐Neto(Center for Diagnosis and Research on Alzheimer's Disease), Linda Karlsson(Lund University), Tammie L.S. Benzinger(Washington University in St. Louis), Heather J. Wiste(Mayo Clinic in Florida), Vincent Doré(Australian e-Health Research Centre)
Nature Aging
March 28, 2025
Cited by 68


Related Papers